NCT06160206View on ClinicalTrials.gov

Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

October 2, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2030

Conditions
Recurrent GlioblastomaRecurrent WHO Grade 4 Glioma
Interventions
BIOLOGICAL

Bevacizumab

Given IV

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT

OTHER

Electronic Health Record Review

Ancillary studies

RADIATION

Hypofractionated Radiation Therapy

Undergo radiation therapy

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

BIOLOGICAL

Retifanlimab

Given IV

Trial Locations (3)

32224

ACTIVE_NOT_RECRUITING

Mayo Clinic in Florida, Jacksonville

55905

RECRUITING

Mayo Clinic, Rochester

85259

ACTIVE_NOT_RECRUITING

Mayo Clinic in Arizona, Scottsdale

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Academic and Community Cancer Research United

OTHER